Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

PURPOSE: FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study of a selective FGFR1–3 inhibitor, infigratinib (BGJ398), in patients with FGFR-altered recurrent gliom...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassman, Andrew B., Sepúlveda-Sánchez, Juan Manuel, Cloughesy, Timothy F., Gil-Gil, Miguel J., Puduvalli, Vinay K., Raizer, Jeffrey J., De Vos, Filip Y.F., Wen, Patrick Y., Butowski, Nicholas A., Clement, Paul M.J., Groves, Morris D., Belda-Iniesta, Cristóbal, Giglio, Pierre, Soifer, Harris S., Rowsey, Steven, Xu, Cindy, Avogadri, Francesca, Wei, Ge, Moran, Susan, Roth, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167702/
https://www.ncbi.nlm.nih.gov/pubmed/35344029
http://dx.doi.org/10.1158/1078-0432.CCR-21-2664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167702/
https://www.ncbi.nlm.nih.gov/pubmed/35344029
http://dx.doi.org/10.1158/1078-0432.CCR-21-2664

Ejemplares similares